Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to tr…

Drug Manufacturers - General

US, Thousand Oaks [HQ]

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Insiders

Form 3/4/5

Transactions

Download

Track non-derivative insider transactions.

i = Indirect d = Direct cs = Common Stock

Download

Reported Owner(s)	Position Now	Transaction Date	Type	Position Change	Extra
Graham Jonathan P EVP & Gen. Counsel & Secy.	$28,903 d cs 10% Holder	12/05/24	G	6,430 x $0 = $0	Footnotes Form 4 - Filed at 12/06/24 #1 These shares were gifted by the reporting person and the reporting person's spouse to two irrevocable trusts for the benefit of the reporting person's adult children. Neither the reporting person nor the reporting person's spouse are trustees of the trusts or otherwise have the power to vote or dispose of the assets held in such trusts. #2 Shares directly beneficially owned also include 550 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested restricted stock units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis upon vesting of the associated RSUs with a cash payment for any remaining fractional share amount.
Bradway Robert A Director	$90,000 i cs 10% Holder	12/02/24	G	90,000 x $0 = $0	Footnotes Form 4 - Filed at 12/03/24 #1 These shares were gifted by the reporting person and the reporting person's spouse to two irrevocable trusts for the benefit of the reporting person's children, subsequent to the same-day transfer by the reporting person of 48,000 shares as separate property of the reporting person's spouse. Neither the reporting person nor the reporting person's spouse are trustees of the children's trusts or otherwise have the power to vote or dispose of the assets held in such trusts. #2 Subsequent to the same-day transfer by the reporting person of 90,000 shares as separate property of the reporting person's spouse, such shares were contributed to a spousal grantor retained annuity trust of which the reporting person and the reporting person's spouse serve as trustees and the reporting person's spouse is the sole annuitant, resulting in indirect ownership by the reporting person of these shares. #3 Shares directly beneficially owned also include 2,141 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested restricted stock units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis upon vesting of the associated RSUs with a cash payment for any remaining fractional share amount.
Bradway Robert A Director	$573,855 d cs 10% Holder	12/02/24	G	96,000 x $0 = $0	Footnotes Form 4 - Filed at 12/03/24 #1 These shares were gifted by the reporting person and the reporting person's spouse to two irrevocable trusts for the benefit of the reporting person's children, subsequent to the same-day transfer by the reporting person of 48,000 shares as separate property of the reporting person's spouse. Neither the reporting person nor the reporting person's spouse are trustees of the children's trusts or otherwise have the power to vote or dispose of the assets held in such trusts. #2 Subsequent to the same-day transfer by the reporting person of 90,000 shares as separate property of the reporting person's spouse, such shares were contributed to a spousal grantor retained annuity trust of which the reporting person and the reporting person's spouse serve as trustees and the reporting person's spouse is the sole annuitant, resulting in indirect ownership by the reporting person of these shares. #3 Shares directly beneficially owned also include 2,141 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested restricted stock units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis upon vesting of the associated RSUs with a cash payment for any remaining fractional share amount.
Bradway Robert A Director	$393,855 d cs 10% Holder	12/02/24	G	90,000 x $0 = $0	Footnotes Form 4 - Filed at 12/03/24 #1 These shares were gifted by the reporting person and the reporting person's spouse to two irrevocable trusts for the benefit of the reporting person's children, subsequent to the same-day transfer by the reporting person of 48,000 shares as separate property of the reporting person's spouse. Neither the reporting person nor the reporting person's spouse are trustees of the children's trusts or otherwise have the power to vote or dispose of the assets held in such trusts. #2 Subsequent to the same-day transfer by the reporting person of 90,000 shares as separate property of the reporting person's spouse, such shares were contributed to a spousal grantor retained annuity trust of which the reporting person and the reporting person's spouse serve as trustees and the reporting person's spouse is the sole annuitant, resulting in indirect ownership by the reporting person of these shares. #3 Shares directly beneficially owned also include 2,141 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested restricted stock units (RSUs) and are paid out in shares of the Company's common stock on a one-to-one basis upon vesting of the associated RSUs with a cash payment for any remaining fractional share amount.
Khosla Rachna SVP, Business Development	$8,383 d cs 10% Holder	11/05/24	F	212 x $316.91 = $67,184.92	Footnotes Form 4 - Filed at 11/06/24 #1 These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Plan): 128 RSUs which will vest on 4/30/2025; 398 RSUs which will vest on 11/5/2025; 407 RSUs which will vest in installments of 200 on 5/2/2025, and 207 on 5/2/2026; 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027; and 532 RSUs which will vest in installments of 175 on 5/7/2026, 176 on 5/7/2027, and 181 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. #2 These shares include 129 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Get PRO Today

With PRO you will unlock 86 more insider transactions for Amgen Inc.

Start Free 7-Day Trial Subscribe to PRO

Statistics

Sample Size: 91 Transactions

Sale (S)

2,117

1.10%

Buy (P)

0.00%

98.90%

Other Ownership

98.90%

Other Ownership

Individuals

We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:

Individuals

We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture: